MORE THAN IMMUNOTHERAPY
'IO, IO,' to ASCO we go: Data parade getting less abstract for Wall Street
By Randy Osborne
With eagerly awaited abstracts unleashed on the world from the American Society of Clinical Oncology (ASCO) annual meeting, pundits and investors were ransacking the batch for clues to success. ASCO unveiled no fewer than 5,000 studies from which results were to be offered at the cancer meeting, which starts in about two weeks.